drugset / Trial / NCT03463525
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
NaSingle-groupOpen-labelOther
Summary
This is an open-label, single centre, Phase I study to determine the brain exposure of \[11C\]osimertinib in patients with EGFRm NSCLC with brain metastases.
Timeline
- Start
- 2018-10-24
- Primary completion
- 2020-03-19
- Completion
- 2020-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [11C]osimertinib | Unknown | — | Intravenous |
| Background | Osimertinib | Small molecule | 80 mg | Oral |